GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Con...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 26, 2024

Coastal Carolina, Southwestern Law School, and Other Institutions Streamline Accessibility Workflows With YuJa's PDF Remediation • Disneyland Resort Celebrates Return of Pixar Fest for a Limited Time, April 26-Aug. 4, 2024 • LENNAR NOW SELLING THREE NEW-HOME COLLECTIONS AT JUNIPERS, SAN DIEGO'S RESORT-STYLE COMMUNITY FOR ACTIVE ADULTS AGED 55 AND BETT • Crescent Point at Niantic Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third St • United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal Healthcare for All™ • Cabot Park Village Senior Living Community Named One of the Country's Best by U.S. News & World Report • Emmy-winning Cyberchase Expands Digital Presence to Engage Every Kid, Everywhere Ahead of Season 15 Premiere • Harbor Point at Centerville Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third • Chase Opens Innovative Branch in Bronx’s Grand Concourse Neighborhood • McCain Foods Plants 18,000 Trees in Wisconsin, Fulfilling 2022 Promise to Plover Community • Carbon Removal and Mariculture Legislation Moves Forward in California Assembly • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer&rs • United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52% • Suzano 2023 annual report on Form 20-F • Dual Enrollment Helps High School Students Launch Rewarding Careers • 29 London Partners With US Media Company Bobi Media to Strengthen Market Offering • Chestnut Park at Cleveland Circle Assisted Living Community Named One of the Country's Best by U.S. News & World Report • The Sallie Mae Fund Grants $75,000 to DC College Access Program to Support Higher Education Access and Completion • Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

ROCKVILLE, Md. , May 31 /Businesswire/ - GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.

A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases with high unmet needs. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition and its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials, planned or potential clinical development, regulatory interactions and submissions, the commercialization and potential benefits and impact of the Company’s drug candidates, and the Company’s expected cash runway. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2022, its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.